The review of our CDP plan was positive and noted that the """"""""potential candidates described were very strong."""""""" However, our reliance on a funding source for senior level post-doctoral fellows was considered """"""""not consistent with the SPORE guidelines."""""""" We have therefore revised the entire CDP to more cleariy provide research support for advanced fellows, junior faculty and established investigators who wish to develop or refocus their careers on translational breast cancer research. CDP support for research fellows through the Thomsen Family Fellowship will be used only when it is for support of research fellows transitioning to independent faculty appointments. In this submission, we have clarified our goals and our adherence to the SPORE guidelines. Our proposed plan describes in detail how promising individuals with an interest in, and expressed commitment to, translational breast cancer research will be selected. It further addresses how the CDP leadership will seek out and recruit qualified women and minorities for participation in the program. More specifically, the CDP Leadership will use program funds to recruit and nurture qualified investigators at all levels. CDP leaders will provide a system for mentoring such individuals in a broad range of disciplines and create a framework in which investigators can gain exposure to, and possibly training in, aspects of translational breast cancer research outside their areas of expertise. Ensuring that innovative ideas can develop into promising translational studies in breast cancer research, and that women, minorities and developing faculty who can make key contributions to translational breast cancer research at the FHCRC and UW, are strongly recruited and retained are also key goals ofthe current plan. In a response to the comment: """"""""Although the commitment to diversity is not questioned, a paragraph stating the gender/minority composition ofthe research programs at FHCRC/UW was not included"""""""", we have added two tables to section C.2 to address this oversight. The first presents the ethnic breakdown of faculty, postdoctoral candidates and pre-doctoral students at FHCRC as of December 31, 2008. The second provides enrollment figures by ethnicity for the UW School of Medicine (UWSOM) in 2007.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
O'Sullivan, Finbarr; O'Sullivan, Janet N; Huang, Jian et al. (2018) Assessment of a statistical AIF extraction method for dynamic PET studies with 15O water and 18F fluorodeoxyglucose in locally advanced breast cancer patients. J Med Imaging (Bellingham) 5:011010
Sorace, Anna G; Partridge, Savannah C; Li, Xia et al. (2018) Distinguishing benign and malignant breast tumors: preliminary comparison of kinetic modeling approaches using multi-institutional dynamic contrast-enhanced MRI data from the International Breast MR Consortium 6883 trial. J Med Imaging (Bellingham) 5:011019
Amornsiripanitch, Nita; Nguyen, Vicky T; Rahbar, Habib et al. (2018) Diffusion-weighted MRI characteristics associated with prognostic pathological factors and recurrence risk in invasive ER+/HER2- breast cancers. J Magn Reson Imaging 48:226-236
Balakrishnan, Ashwini; Goodpaster, Tracy; Randolph-Habecker, Julie et al. (2017) Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues. Clin Cancer Res 23:3061-3071
Wangerin, Kristen A; Muzi, Mark; Peterson, Lanell M et al. (2017) A virtual clinical trial comparing static versus dynamic PET imaging in measuring response to breast cancer therapy. Phys Med Biol 62:3639-3655
Rahbar, Habib; McDonald, Elizabeth S; Lee, Janie M et al. (2016) How Can Advanced Imaging Be Used to Mitigate Potential Breast Cancer Overdiagnosis? Acad Radiol 23:768-73
Sommermeyer, D; Hudecek, M; Kosasih, P L et al. (2016) Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 30:492-500
Liu, Lingfeng; Sommermeyer, Daniel; Cabanov, Alexandra et al. (2016) Inclusion of Strep-tag II in design of antigen receptors for T-cell immunotherapy. Nat Biotechnol 34:430-4
Rahbar, Habib; Partridge, Savannah C (2016) Multiparametric MR Imaging of Breast Cancer. Magn Reson Imaging Clin N Am 24:223-238
Rahbar, Habib; Parsian, Sana; Lam, Diana L et al. (2016) Can MRI biomarkers at 3 T identify low-risk ductal carcinoma in situ? Clin Imaging 40:125-9

Showing the most recent 10 out of 54 publications